Virtual Nodule Clinic
AI-powered lung nodule management platform for early lung cancer detection
Company profile
Company profile
Optellum is a healthcare AI company focused on transforming lung cancer care through early detection and precision diagnosis. The company has developed the Virtual Nodule Clinic, an AI-powered platform that assists clinicians in identifying, tracking, and managing pulmonary nodules detected in CT scans. By leveraging advanced machine learning algorithms, Optellum's technology helps healthcare providers stratify patient risk, optimize follow-up protocols, and make more informed clinical decisions about lung nodules that may be cancerous. The platform is designed to integrate into existing radiology and pulmonology workflows, supporting earlier intervention and improved patient outcomes. Optellum serves health systems, hospitals, and imaging centers globally, with a particular focus on lung cancer screening programs and incidental nodule management. The company's mission centers on reducing lung cancer mortality through the application of artificial intelligence to one of oncology's most challenging diagnostic problems. Founded by a team combining expertise in machine learning, clinical medicine, and healthcare technology, Optellum has gained regulatory clearances and clinical validation for its approach to precision lung health.
Company description Optellum official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas deployment with recorded integration context.
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
AI-powered lung nodule management platform for early lung cancer detection
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
CHEST pulmonary · Jun 1, 2026
Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules.PloS one · Jan 1, 2026
Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study.BMJ open respiratory research · Nov 17, 2025
Deep Learning Models for Predicting Malignancy Risk in CT-Detected Pulmonary Nodules: A Systematic Review and Meta-analysis.Lung · Oct 1, 2024
Clinical utility of an artificial intelligence radiomics-based tool for risk stratification of pulmonary nodules.JNCI cancer spectrum · Sep 2, 2024
Determining the impact of an artificial intelligence tool on the management of pulmonary nodules detected incidentally on CT (DOLCE) study protocol: a prospective, non-interventional multicentre UK study.BMJ open · Jan 4, 2024
Clinical validation
No linked records are currently available.
Regulatory
K202300 · 510k · Mar 5, 2021
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Optellum's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.